We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$96B
AUM Growth
-$1.03B
Cap. Flow
-$1.11B
Cap. Flow %
-1.16%
Top 10 Hldgs %
36.39%
Holding
500
New
14
Increased
150
Reduced
126
Closed
12

Top Buys

Rank Stock Value
1
TEAM icon
Atlassian
TEAM
+$350M
2
NVDA icon
NVIDIA
NVDA
+$308M
3
MELI icon
Mercado Libre
MELI
+$305M
4
RBLX icon
Roblox
RBLX
+$300M
5
NIO icon
NIO
NIO
+$280M

Sector Composition

Rank Sector Weight
1 Healthcare 27.94%
2 Consumer Discretionary 24.48%
3 Technology 18.24%
4 Communication Services 10.28%
5 Financials 7.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
APLS
376
DELISTED
Apellis Pharmaceuticals
APLS
$14.6K ﹤0.01%
283
LOGI icon
377
Logitech
LOGI
$15.2B
$14.5K ﹤0.01%
235
TGT icon
378
Target
TGT
$68B
$14.5K ﹤0.01%
97
VRNT
379
DELISTED
Verint Systems
VRNT
$14.3K ﹤0.01%
395
INSM icon
380
Insmed
INSM
$28.6B
$14.1K ﹤0.01%
707
GNTX icon
381
Gentex
GNTX
$5.07B
$14.1K ﹤0.01%
516
SMAR
382
DELISTED
Smartsheet Inc.
SMAR
$13.9K ﹤0.01%
352
DKNG icon
383
DraftKings
DKNG
$11.9B
$13.8K ﹤0.01%
1,214
BPMC
384
DELISTED
Blueprint Medicines
BPMC
$13.8K ﹤0.01%
315
MXL icon
385
MaxLinear
MXL
$6.8B
$13.8K ﹤0.01%
405
ADEA icon
386
Adeia
ADEA
$3.11B
$13.7K ﹤0.01%
1,448
-4,025
-74% -$41K
GTM
387
ZoomInfo Technologies
GTM
$1.22B
$13.4K ﹤0.01%
446
+62
+16% +$2.14K
PAYX icon
388
Paychex
PAYX
$42.7B
$13.4K ﹤0.01%
116
INCY icon
389
Incyte
INCY
$24.4B
$13.3K ﹤0.01%
165
LECO icon
390
Lincoln Electric
LECO
$15.4B
$13.1K ﹤0.01%
91
FOXA icon
391
Fox Class A
FOXA
$26.9B
$13.1K ﹤0.01%
430
+68
+19% +$2.08K
WDFC icon
392
WD-40
WDFC
$3.15B
$12.9K ﹤0.01%
80
+13
+19% +$2.17K
ACN icon
393
Accenture
ACN
$108B
$12.8K ﹤0.01%
48
LHX icon
394
L3Harris
LHX
$53.4B
$12.7K ﹤0.01%
61
CHRS icon
395
Coherus Oncology
CHRS
$196M
$12.6K ﹤0.01%
1,585
SILK
396
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$12.4K ﹤0.01%
235
SWKS icon
397
Skyworks Solutions
SWKS
$10.6B
$12.4K ﹤0.01%
136
AXNX
398
DELISTED
Axonics, Inc. Common Stock
AXNX
$12.4K ﹤0.01%
198
TENB icon
399
Tenable Holdings
TENB
$4.01B
$12K ﹤0.01%
315
CRWD icon
400
CrowdStrike
CRWD
$218B
$12K ﹤0.01%
456

Similar funds

Baillie Gifford & Co's Q4 2022 Portfolio in Review

As of Q4 2022, Baillie Gifford & Co held 500 positions worth $96B, down 1.1% from $97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Baillie Gifford & Co's Q4 2022 filing shows 14 new, 150 increased, 126 reduced and 12 closed positions. Its largest new stake was Eaton: 1,452,086 shares worth $228M. The largest sale was Abiomed Inc, an estimated $1.21B.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Baillie Gifford & Co's largest Q4 2022 buy was Eaton: 1,452,086 shares worth $228M.
  • Baillie Gifford & Co added most to Atlassian in Q4 2022, an estimated $350M increase.
  • Baillie Gifford & Co's biggest Q4 2022 reduction was Abiomed Inc, cutting an estimated $1.21B.
  • Baillie Gifford & Co fully exited Li Auto in Q4 2022, selling an estimated $134M.
  • Baillie Gifford & Co's ten largest holdings make up 36% of its $96B portfolio in Q4 2022.
  • Baillie Gifford & Co opened 14 new positions and closed 12 in Q4 2022.
  • Baillie Gifford & Co's portfolio value fell 1.1% quarter-over-quarter to $96B.

Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.